DOCSLIB.ORG

Compositions for Treating Itch Zusammensetzungen Zur Behandlung Von Juckreiz Compositions Pour Traiter Les Démangeaisons

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Compositions for Treating Itch Zusammensetzungen Zur Behandlung Von Juckreiz Compositions Pour Traiter Les Démangeaisons (19) TZZ Z¥_T (11) EP 2 446 903 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: A61K 31/085 (2006.01) A61K 31/165 (2006.01) 09.10.2019 Bulletin 2019/41 A61K 31/167 (2006.01) A61K 31/14 (2006.01) A61K 9/00 (2006.01) A61K 45/06 (2006.01) (2006.01) (2006.01) (21) Application number: 11007949.8 A61P 17/04 A61P 29/00 (22) Date of filing: 19.11.2007 (54) Compositions for treating itch Zusammensetzungen zur Behandlung von Juckreiz Compositions pour traiter les démangeaisons (84) Designated Contracting States: WO-A2-99/11252 US-A- 3 519 631 AT BE BG CH CY CZ DE DK EE ES FI FR GB GR US-A- 4 069 309 US-B1- 6 362 197 HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE US-B1- 6 413 961 SI SK TR • OMANA-ZAPATA I ET AL: "QX-314 inhibits (30) Priority: 20.11.2006 US 860124 P ectopic nerve activity associated with 06.07.2007 US 958594 P neuropathic pain.", BRAIN RESEARCH 17 OCT 03.10.2007 US 997510 P 1997,vol. 771, no. 2, 17 October 1997 (1997-10-17), pages 228-237, XP002486707, ISSN: 0006-8993 (43) Date of publication of application: • STRICHARTZ G R: "The inhibition of sodium 02.05.2012 Bulletin 2012/18 currents in myelinated nerve by quaternary derivatives of lidocaine.", THE JOURNAL OF (62) Document number(s) of the earlier application(s) in GENERAL PHYSIOLOGY JUL 1973, vol. 62, no. 1, accordance with Art. 76 EPC: July 1973 (1973-07), pages 37-57, XP002486708, 07862114.1 / 2 101 819 ISSN: 0022-1295 • CAHALAN M D ET AL: "Interactions between (73) Proprietors: quaternary lidocaine, the sodium channel gates, • President and Fellows of Harvard College andtetrodotoxin.", BIOPHYSICAL JOURNAL JUL Cambridge, MA 02138 (US) 1979, vol. 27, no. 1, July 1979 (1979-07), pages • The General Hospital Corporation 39-55, XP002486709, ISSN: 0006-3495 Boston, MA 02114 (US) • RICH T C ET AL: "Quaternary quinidine derivatives as a tool to study: Block of human (72) Inventors: potassium channels", BIOPHYSICAL JOURNAL, • Bean, Bruce P. vol. 66, no. 2 PART 2, 1994, page A143, Waban, MA 02468 (US) XP009102646, & THIRTY-EIGHTH ANNUAL • Woolf, Clifford J. MEETING OF THE BIOPHYSICAL SOCIETY; NEW Newton, MA 02458 (US) ORLEANS, LOUISIANA, USA; MARCH 6-10, 1994 ISSN: 0006-3495 (74) Representative: Lahrtz, Fritz et al • KIRKPATRICK W E ET AL: "Comparison of the Patentanwälte effects of procaine, chlorpromazine and their Isenbruck Bösl Hörschler PartG mbB quaternary derivatives on nerve action Prinzregentenstraße 68 potentials.", RESEARCH COMMUNICATIONS IN 81675 München (DE) CHEMICAL PATHOLOGY AND PHARMACOLOGY JAN 1970, vol. 1, no. 1, (56) References cited: January 1970 (1970-01), pages 149-155, WO-A-01/44218 WO-A1-98/24428 XP009102648, ISSN: 0034-5164 WO-A1-2006/010587 WO-A2-01/45678 Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention). EP 2 446 903 B1 Printed by Jouve, 75001 PARIS (FR) (Cont. next page) EP 2 446 903 B1 • NIELSEN A B ET AL: "Assessment of the • Scott M Fishman ET AL: "BRIEF CLINICAL combined approach of N-alkylation and salt OBSERVATIONS Intravenous Lidocaine for formation to enhance aqueous solubility of Treatment-resistant Pruritus", The American tertiary amines using bupivacaine as a model Journal of Medicine, vol. 102, 1 June 1997 drug", EUROPEAN JOURNAL OF (1997-06-01), pages 584-585, XP055479315, PHARMACEUTICAL SCIENCES, ELSEVIER, • Martin Steinhoff ET AL: "Neurophysiological, AMSTERDAM, NL, vol. 24, no. 1, 1 January 2005 Neuroimmunological,and Neuroendocrine Basis (2005-01-01), pages 85-93, XP027803616, ISSN: of Pruritus", Journal of Investigative 0928-0987 [retrieved on 2005-01-01] Dermatology, vol. 126, no. 8, 1 August 2006 • NIELSEN A B ET AL: "Bioreversible quaternary (2006-08-01), pages 1705-1718, XP055141873, N-acyloxymethyl derivatives of the tertiary ISSN: 0022-202X, DOI: 10.1038/sj.jid.5700231 amines bupivacaine and lidocaine-synthesis, aqueous solubility and stability in buffer, human plasma and simulated intestinal fluid", EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES,ELSEVIER, AMSTERDAM, NL, vol. 24, no. 5, 1 April 2005 (2005-04-01), pages 433-440, XP027803766, ISSN: 0928-0987 [retrieved on 2005-04-01] 2 EP 2 446 903 B1 Description Background of the Invention 5 [0001] The invention features uses in methods, compositions, and kits for selective inhibition of pain-and itch sensing neurons (nociceptors and pruriceptors) by drug molecules of small molecule weight, while minimizing effects on non- pain-sensing neurons or other types of cells. According to the invention, small, hydrophilic drug molecules gain access to the intracellular compartment of pain-sensing neurons via entry through receptors that are present in pain- and itch- sensing neurons but to a lesser extent or not at all in other types of neurons or in other types of tissue. 10 [0002] Local anesthetics such as lidocaine and articaine act by inhibiting voltage-dependent sodium channels in neurons. These anesthetics block sodium channels and thereby the excitability of all neurons, not just pain-sensing neurons (nociceptors). Thus, while the goal of topical or regional anesthesia is to block transmission of signals in nociceptors to prevent pain, administration of local anesthetics also produces unwanted or deletrious effects such as general numbness from block of low threshold pressure and touch receptors, motor deficits from block of motor axons 15 and other complications from block of autonomic fibers. Local anesthetics are relatively hydrophobic molecules that gain access to their blocking site on the sodium channel by diffusing into or through the cell membrane. Permanently-charged derivatives of these compounds (such as QX-314, a quaternary nitrogen derivative of lidocaine), which are not membrane- permeant, have no effect on neuronal sodium channels when applied to the external surface of the nerve membrane but can block sodium channels if somehow introduced inside the cell, for example by a micropipette used for whole-cell 20 electrophysiological recording from isolated neurons. Pain-sensing neurons differ from other types of neurons in ex- pressing (in most cases) the TRPV1 receptor/channel, activated by painful heat or by capsaicin, the pungent ingredient in chili pepper. Other types of receptors selectively expressed in various types of pain-sensing and itch-sensing (pruri- ceptor) neurons include but are not limited to TRPA1, TRPM8, and P2X(2/3) receptors. [0003] Neuropathic, inflammatory, and nociceptive pain differ in their etiology, pathophysiology, diagnosis, and treat- 25 ment. Nociceptive pain occurs in response to the activation of a specific subset of peripheral sensory neurons, the nociceptors by intense or noxious stimuli. It is generally acute, self-limiting and serves a protective biological function by acting as a warning of potential or on-going tissue damage. It is typically well-localized. Examples of nociceptive pain include but are not limited to traumatic or surgical pain, labor pain, sprains, bone fractures, burns, bumps, bruises, injections, dental procedures, skin biopsies, and obstructions. 30 [0004] Inflammatory pain is pain that occurs in the presence of tissue damage or inflammation including postoperative, post-traumatic pain, arthritic (rheumatoid or osteoarthritis) pain and pain associated with damage to joints, muscle, and tendons as in axial low back pain. [0005] Neuropathic pain is a common type of chronic, non-malignant pain, which is the result of an injury or malfunction in the peripheral or central nervous system and serves no protective biological function. It is estimated to affect more 35 than 1.6 million people in the U.S. population. Neuropathic pain has many different etiologies, and may occur, for example, due to trauma, surgery, herniation of an intervertebral disk, spinal cord injury, diabetes, infection with herpes zoster (shingles), HIV/AIDS, late-stage cancer, amputation (including mastectomy), carpal tunnel syndrome, chronic alcohol use, exposure to radiation, and as an unintended side-effect of neurotoxic treatment agents, such as certain anti-HIV and chemotherapeutic drugs. 40 [0006] In contrast to nociceptive pain, neuropathic pain is frequently described as "burning," "electric," "tingling," or "shooting" in nature. It is often characterized by chronic allodynia (defined as pain resulting from a stimulus that does not ordinarily elicit a painful response, such as light touch) and hyperalgesia (defined as an increased sensitivity to a normally painful stimulus), and may persist for months or years beyond the apparent healing of any damaged tissues. [0007] Pain may occur in patients with cancer, which may be due to multiple causes; inflammation, compression, 45 invasion, metastatic spread into bone or other tissues. [0008] There are some conditions where pain occurs in the absence of a noxious stimulus, tissue damage or a lesion to the nervous system, called dysfunctional pain and these include but are not limited to fibromyalgia, tension type headache, irritable bowel disorders and erythermalgia. [0009] Migraine is a headache associated with the activation of sensory fibers innervating the meninges of the brain. 50 [0010] Itch (pruritus) is a dermatological condition that may be localized and generalized and can be associated with skin lesions (rash, atopic eczema, wheals). Itch accompanies many conditions including but not limited to stress, anxiety, UV radiation from the sun, metabolic and endocrine disorders (e.g., liver or kidney disease, hyperthyroidism), cancers (e.g., lymphoma), reactions to drugs or food, parasitic and fungal infections, allergic reactions, diseases of the blood (e.g., polycythemia vera), and dermatological conditions.
Load more

Recommended publications
  • Chapter 6—Clove Oil (Eugenol)
    Chapter 6—Clove Oil (Eugenol) OH CH3 O Eugenol Chapter 6: Clove oil 6-2 6 Table of Contents — Clove Oil (Eugenol) 6.1 INTRODUCTION ......................................................................................................................................... 6-4 6.2 CLOVE OIL AND EUGENOL TOXICITY TO HUMANS AND LEVELS OF CONCERN ................ 6-6 6.2.1 HEALTH EFFECTS ...................................................................................................................................... 6-7 6.2.1.A Acute Effects—Sensitization ........................................................................................................... 6-7 6.2.1.B Acute Effects—Skin, Eyes and Respiratory System ........................................................................ 6-7 6.2.1.C Acute Effects—Systemic Poisoning ................................................................................................ 6-7 6.2.1.D Effects in Human Cells .................................................................................................................... 6-8 6.2.1.E Levels of Concern for Humans ........................................................................................................ 6-8 6.2.2 PESTICIDE ILLNESS REPORTS .................................................................................................................... 6-9 6.3 EUGENOL TOXICITY TO ANIMALS AND PLANTS AND LEVELS OF CONCERN .................... 6-10 6.3.1 MAMMALS .............................................................................................................................................
    [Show full text]
  • Understanding and Managing the Transition Using Essential Oils Vs
    MENOPAUSE: UNDERSTANDING AND MANAGING THE TRANSITION USING ESSENTIAL OILS VS. TRADITIONAL ALLOPATHIC MEDICINE by Melissa A. Clanton A thesis submitted in partial fulfillment of the requirements for the Diploma of Aromatherapy 401 Australasian College of Health Sciences Instructors: Dorene Petersen, Erica Petersen, E. Joy Bowles, Marcangelo Puccio, Janet Bennion, Judika Illes, and Julie Gatti TABLE OF CONTENTS List of Tables and Figures............................................................................ iv Acknowledgments........................................................................................ v Introduction.................................................................................................. 1 Chapter 1 – Female Reproduction 1a – The Female Reproductive System............................................. 4 1b - The Female Hormones.............................................................. 9 1c – The Menstrual Cycle and Pregnancy....................................... 12 Chapter 2 – Physiology of Menopause 2a – What is Menopause? .............................................................. 16 2b - Physiological Changes of Menopause ..................................... 20 2c – Symptoms of Menopause ....................................................... 23 Chapter 3 – Allopathic Approaches To Menopausal Symptoms 3a –Diagnosis and Common Medical Treatments........................... 27 3b – Side Effects and Risks of Hormone Replacement Therapy ...... 32 3c – Retail Cost of Common Hormone Replacement
    [Show full text]
  • Oxidation of Geraniol Using Niobia Modified With
    Revista Facultad de Ingeniería, Universidad de Antioquia, No.91, pp. 106-112, Apr-Jun 2019 Oxidation of geraniol using niobia modified with hydrogen peroxide Oxidación de geraniol utilizando niobia modificada con peróxido de hidrógeno Jairo Cubillos 1*, Jose J. Martínez 1, Hugo Rojas 1, Norman Marín-Astorga2 1Grupo de Catálisis, Escuela de Ciencias Químicas, Universidad Pedagógica y Tecnológica de Colombia UPTC. Avenida Central del Norte 39-115. A.A. 150003 Tunja. Boyacá, Colombia. 2Eurecat U.S. Incorporated. 13100 Bay Park Rd. C.P. 77507. Pasadena, Texas, USA. ABSTRACT: Nb2O5 bulk and Nb2O5 modified with H2O2 were studied in the epoxidation of geraniol at 1 bar and room temperature. The structural and morphological properties ARTICLE INFO: for both catalysts were very similar, indicating that the peroxo-complex species were not Received: April 27, 2018 formed. The order of the reaction was one with respect to geraniol and close to zero respect Accepted: April 16, 2019 to H2O2, these values fit well with the kinetic data obtained. The geraniol epoxidation is favored by the presence of peroxo groups, which is reached using an excess of H2O2. Moreover, the availability of the geraniol to adopt the three-membered-ring transition state AVAILABLE ONLINE: was found as the best form for this type of compound. April 22, 2019 RESUMEN: El óxido de niobio (niobia), Nb2O5 y Nb2O5 modificado con H2O2 fue explorado como catalizador en la epoxidación de geraniol a 1 bar y temperatura ambiente. Las KEYWORDS: propiedades estructurales y morfológicas de ambos catalizadores fueron muy similares, Niobium oxide, peroxo lo cual sugiere que no se formaron especies de complejo peroxo.
    [Show full text]
  • The Effects of Eugenol, Trans-Cinnamaldehyde, Citronellol
    molecules Article The Effects of Eugenol, Trans-Cinnamaldehyde, Citronellol, and Terpineol on Escherichia coli Biofilm Control as Assessed by Culture-Dependent and -Independent Methods Magdalena A. Olszewska 1,* , Astrid G˛edas 1 and Manuel Simões 2,* 1 Department of Industrial and Food Microbiology, Faculty of Food Science, University of Warmia and Mazury in Olsztyn, Plac Cieszy´nski1, 10-726 Olsztyn, Poland; [email protected] 2 LEPABE–Department of Chemical Engineering, Faculty of Engineering, University of Porto, 4200-465 Porto, Portugal * Correspondence: [email protected] (M.A.O.); [email protected] (M.S.); Tel.: +48-89-5233729 (M.A.O.); +351-22508-1654 (M.S.); Fax: +351-22508-1449 (M.S.) Received: 14 May 2020; Accepted: 5 June 2020; Published: 6 June 2020 Abstract: Bacterial biofilms contribute to problems with preserving food hygiene, jeopardizing any conventional intervention method used by the food industry. Hence, the approach of using essential oil (EO) compounds effective in biofilm control has considerable merit and deserves in-depth research. In this study, the effect of selected EO compounds (eugenol, trans-cinnamaldehyde, citronellol, and terpineol) was assessed on Escherichia coli biofilm control by plate count, resazurin assay, and Syto® 9/PI (-/propidium iodide) staining coupled with flow cytometry (FCM) and confocal laser scanning microscopy (CLSM). The selected EO compounds effectively inhibited the growth of planktonic E. coli at low concentrations of 3–5 mM, revealing a high antimicrobial activity. EO compounds markedly interfered with biofilms too, with trans-cinnamaldehyde causing the most prominent effects. Its antibiofilm activity was manifested by a high reduction of cell metabolic activity (>60%) and almost complete reduction in biofilm cell culturability.
    [Show full text]
  • The Synthesis of Vanillin
    The synthesis of vanillin - learning about aspects of sustainable chemistry by comparing different syntheses La síntesis de la vainilla - aprendiendo sobre aspectos de química sostenible mediante la comparación de diferentes síntesis NICOLE GARNER1, ANTJE SIOL2 , INGO EILKS1 1 Institute for Science Education, University of Bremen, 2 Center for Environmental Research and Sustainable Technology, University of Bremen, Germany, [email protected] Abstract • Prevention This paper discusses one way of integrating the aspects of sustainable chemistry into • Atom Economy secondary and undergraduate chemistry education. Two different synthesis reactions • Less Hazardous Chemical Syntheses for vanillin are presented, which both use isoeugenol as the starting reagent. Whereas • Designing Safer Chemicals the first synthesis is performed using conventional chemistry techniques, second • Safer Solvents and Auxiliaries approach employs strategies inspired by sustainable chemistry. The discussion • Design for Energy Efficiency covers how comparison of these two experiments can aid in learning about selected • Use of Renewable Feedstocks sustainable chemistry principles. • Reduce Derivatives Key words: education for sustainable development, chemistry education, green • Catalysis chemistry, vanillin • Design for Degradation • Real-time Analysis for Pollution Prevention Resumen • Inherently Safer Chemistry for Accident Prevention Este artículo analiza una manera de integrar los aspectos de la química sostenible en la escuela secundaria y en bachillerato.
    [Show full text]
  • Searching for Novel Cancer Chemopreventive Plants and Their Products: the Genus Zanthoxylum
    Current Drug Targets, 2011, 12, 1895-1902 1895 Searching for Novel Cancer Chemopreventive Plants and their Products: The Genus Zanthoxylum Francesco Epifano*,1, Massimo Curini2, Maria Carla Marcotullio2 and Salvatore Genovese1 1Dipartimento di Scienze del Farmaco, Università “G. D’Annunzio” di Chieti-Pescara, Via dei Vestini 31, 66013 Chieti Scalo (CH), Italy 2Dipartimento di Chimica e Tecnologia del Farmaco, Sezione di Chimica Organica, Università degli Studi di Perugia, Via del Liceo, 06123 Perugia, Italy Abstract: The genus Zanthoxylum (Rutaceae) comprises about 250 species, of which many are used as food, often as condiments, substituting pepper due to the pungent taste of fruits, seeds, leaves, and bark, and therapeutic remedies especially in Eastern Asian countries and in Central America. The whole plant is also consumed as an ingredient of soups and salads. The aim of this review is to examine in detail from a phytochemical and pharmacological point of view what is reported in the current literature about the anti-cancer and chemopreventive properties of phytopreparations or individual active compounds obtained from edible plants belonging to this genus. Keywords: Anti-cancer activity, cancer chemoprevention, edible plants, prenyloxyphenylpropanoids, Rutaceae, Zanthoxylum. INTRODUCTION EDIBLE PLANTS OF THE GENUS ZANTHOXYLUM EXHIBITING ANTI-CANCER PROPERTIES Cancer is nowadays one of the major causes of death all over the world. Although many therapeutic remedies have Zanthoxylum ailanthoides Siebold & Zucc. been developed and used, most of which with appreciable Zanthoxylum ailanthoides, commonly known as success, prevention and cure of this severe syndrome is a “Japanese prickly-ash”, is a plant originary of the East-Asia, research field of current interest.
    [Show full text]
  • Catalytic Activities of Tumor-Specific Human Cytochrome P450 CYP2W1 Toward Endogenous Substrates S
    Supplemental material to this article can be found at: http://dmd.aspetjournals.org/content/suppl/2016/03/02/dmd.116.069633.DC1 1521-009X/44/5/771–780$25.00 http://dx.doi.org/10.1124/dmd.116.069633 DRUG METABOLISM AND DISPOSITION Drug Metab Dispos 44:771–780, May 2016 Copyright ª 2016 by The American Society for Pharmacology and Experimental Therapeutics Catalytic Activities of Tumor-Specific Human Cytochrome P450 CYP2W1 Toward Endogenous Substrates s Yan Zhao, Debin Wan, Jun Yang, Bruce D. Hammock, and Paul R. Ortiz de Montellano Department of Pharmaceutical Chemistry, University of California, San Francisco (Y.Z., P.R.O.M.) and Department of Entomology and Cancer Center, University of California, Davis, CA (D.W., J.Y., B.D.H.) Received January 25, 2015; accepted February 29, 2016 ABSTRACT CYP2W1 is a recently discovered human cytochrome P450 enzyme 4-OH all-trans retinol, and it also oxidizes retinal. The enzyme much with a distinctive tumor-specific expression pattern. We show here less efficiently oxidizes 17b-estradiol to 2-hydroxy-(17b)-estradiol and that CYP2W1 exhibits tight binding affinities for retinoids, which have farnesol to a monohydroxylated product; arachidonic acid is, at best, Downloaded from low nanomolar binding constants, and much poorer binding constants a negligible substrate. These findings indicate that CYP2W1 probably in the micromolar range for four other ligands. CYP2W1 converts all- plays an important role in localized retinoid metabolism that may be trans retinoic acid (atRA) to 4-hydroxy atRA and all-trans retinol to intimately linked to its involvement in tumor development.
    [Show full text]
  • Novel Intranasal Drug Delivery: Geraniol Charged Polymeric Mixed Micelles for Targeting Cerebral Insult As a Result of Ischaemia/Reperfusion
    pharmaceutics Article Novel Intranasal Drug Delivery: Geraniol Charged Polymeric Mixed Micelles for Targeting Cerebral Insult as a Result of Ischaemia/Reperfusion Sara M. Soliman 1, Nermin M. Sheta 1, Bassant M. M. Ibrahim 2, Mohammad M. El-Shawwa 3 and Shady M. Abd El-Halim 1,* 1 Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, 6th of October University, Central Axis, Sixth of October City, Giza 12585, Egypt; [email protected] (S.M.S.); [email protected] (N.M.S.) 2 Department of Pharmacology, Medical Research Division, National Research Centre, Dokki, Giza 12622, Egypt; [email protected] 3 Department of Physiology, Faculty of Medicine for Girls, Al-Azhar University, Cairo 11651, Egypt; [email protected] * Correspondence: [email protected]; Tel.: +20-11-199-94874 Received: 16 November 2019; Accepted: 13 January 2020; Published: 17 January 2020 Abstract: Brain damage caused by cerebral ischaemia/reperfusion (I/R) can lead to handicapping. So, the present study aims to evaluate the prophylactic and therapeutic effects of geraniol in the form of intranasal polymeric mixed micelle (PMM) on the central nervous system in cerebral ischaemia/reperfusion (I/R) injury. A 32 factorial design was used to prepare and optimize geraniol PMM to investigate polymer and stabilizer different concentrations on particle size (PS) and percent entrapment efficiency (%EE). F3 possessing the highest desirability value (0.96), with a PS value of 32.46 0.64 nm, EE of 97.85 1.90%, and release efficiency of 59.66 0.64%, was selected for ± ± ± further pharmacological and histopathological studies. In the prophylactic study, animals were classified into a sham-operated group, a positive control group for which I/R was done without treatment, and treated groups that received vehicle (plain micelles), geraniol oil, and geraniol micelles intranasally before and after I/R.
    [Show full text]
  • Lemongrass Essential Oil Components with Antimicrobial and Anticancer Activities
    Preprints (www.preprints.org) | NOT PEER-REVIEWED | Posted: 21 June 2021 doi:10.20944/preprints202106.0500.v1 Review Lemongrass essential oil components with antimicrobial and anticancer activities Mohammad Mukarram 1,2,*, Sadaf Choudhary 1 , Mo Ahamad Khan 3 , Palmiro Poltronieri 4,* , M. Masroor A. Khan 1 , Jamin Ali 5 , Daniel Kurjak 2 and Mohd Shahid 6 1 Advance Plant Physiology Section, Department of Botany, Aligarh Muslim University, Aligarh 202002, India; [email protected] (M.M.); [email protected] (S.C.); [email protected] (M.M.A.K.) 2 Department of Integrated Forest and Landscape Protection, Faculty of Forestry, Technical University in Zvolen, T. G. Masaryka 24, 96001, Zvolen, Slovakia; [email protected] (D.K.) 3 Department of Microbiology, Jawaharlal Nehru Medical College, Aligarh Muslim University, Aligarh 202002, India; [email protected] (M.A.K.) 4 Institute of Sciences of Food Productions, ISPA-CNR, National Research Council of Italy, via Monteroni km 7, 73100 Lecce, Italy; [email protected] (P.P.) 5 Centre for Applied Entomology & Parasitology, School of Life Sciences, Keele University, United Kingdom; [email protected] (J.A.) 6 Department of Microbiology, Immunology & Infectious Diseases, College of Medicine & Medical Sciences, Arabian Gulf University, Kingdom of Bahrain; [email protected] (M.S.) * Correspondence: [email protected] (P.P.); [email protected] (M.M.) Abstract: The prominent cultivation of lemongrass relies on the pharmacological incentives of its essential oil. The lemongrass essential oil (LEO) has a significant amount of citral (mixture of geranial and neral), isoneral, isogeranial, geraniol, geranyl acetate, citronellal, citronellol, germacrene-D, and elemol in addition to numerous other bioactive compounds.
    [Show full text]
  • Electroanalysis May Be Used in the Vanillin Biotechnological Production
    CORE Metadata, citation and similar papers at core.ac.uk Provided by Open Archive Toulouse Archive Ouverte OATAO is an open access repository that collects the work of Toulouse researchers and makes it freely available over the web where possible This is an author’s version published in: http://oatao.univ-toulouse.fr/20317 Official URL: https://doi.org/10.1007/s12010-013-0631-2 To cite this version: Giraud, William and Mirabel, Marie and Comtat, Maurice Electroanalysis may be used in the Vanillin Biotechnological Production. (2014) Applied Chemistry and Biotechnology, 172 (4). 1953-1963. ISSN 0273-2289 Any correspondence concerning this service should be sent to the repository administrator: [email protected] Electroanalysis may be used in the Vanillin Biotechnological Production William Giraud & Marie Mirabel & Maurice Comtat Abstract This study shows that electroanalysis may be used in vanillin biotechnological production. As a matter of fact, vanillin and some molecules implicated in the process like eugenol, ferulic acid, and vanillic acid may be oxidized on electrodes made of different materials (gold, platinum, glassy carbon). By a judicious choice of the electrochemical method and the experimental conditions the current intensity is directly proportional to the molecule concentrations in a range suitable for the biotechnological process. So, it is possible to imagine some analytical strategies to control some steps in the vanillin biotechnological production: by sampling in the batch reactor during the process, it is possible to determine out of line the concentration of vanillin, eugenol, ferulic acid, and vanillic acid with a gold rotating disk electrode, and low concentration of vanillin with addition of hydrazine at an amalgamated electrode.
    [Show full text]
  • Combination of the Natural Product Capsaicin and Docetaxel
    Sánchez et al. Cancer Cell Int (2019) 19:54 https://doi.org/10.1186/s12935-019-0769-2 Cancer Cell International PRIMARY RESEARCH Open Access Combination of the natural product capsaicin and docetaxel synergistically kills human prostate cancer cells through the metabolic regulator AMP-activated kinase Belén G. Sánchez1, Alicia Bort1, Pedro A. Mateos‑Gómez1, Nieves Rodríguez‑Henche1 and Inés Díaz‑Laviada1,2* Abstract Background: Current chemotherapy for castration‑resistant prostate cancer is established on taxane‑based com‑ pounds like docetaxel. However, eventually, the development of toxic side efects and resistance limits the thera‑ peutic beneft being the major concern in the treatment of prostate cancer. Combination therapies in many cases, enhance drug efcacy and delay the appearance of undesired efects, representing an important option for the treat‑ ment of castration‑resistant prostate cancer. In this study, we tested the efcacy of the combination of docetaxel and capsaicin, the pungent ingredient of hot chili peppers, on prostate cancer cells proliferation. Methods: Prostate cancer LNCaP and PC3 cell lines were used in this study. Levels of total and phosphorylated forms of Akt, mTOR, S6, LKB1, AMPK and ACC were determined by Western blot. AMPK, LKB1 and Akt knock down was performed by siRNA. PTEN was overexpressed by transient transfection with plasmids. Xenograft prostate tumors were induced in nude mice and treatments (docetaxel and capsaicin) were administered intraperitoneally. Statistical analyses were performed with GraphPad software. Combination index was calculated with Compusyn software. Results: Docetaxel and capsaicin synergistically inhibited the growth of LNCaP and PC3 cells, with a combina‑ tion index lower than 1 for most of the combinations tested.
    [Show full text]
  • Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set
    MTC eHealth DSI [eHDSI v2.2.2-OR] eHealth DSI – Master Value Set Catalogue Responsible : eHDSI Solution Provider PublishDate : Wed Nov 08 16:16:10 CET 2017 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 1 of 490 MTC Table of Contents epSOSActiveIngredient 4 epSOSAdministrativeGender 148 epSOSAdverseEventType 149 epSOSAllergenNoDrugs 150 epSOSBloodGroup 155 epSOSBloodPressure 156 epSOSCodeNoMedication 157 epSOSCodeProb 158 epSOSConfidentiality 159 epSOSCountry 160 epSOSDisplayLabel 167 epSOSDocumentCode 170 epSOSDoseForm 171 epSOSHealthcareProfessionalRoles 184 epSOSIllnessesandDisorders 186 epSOSLanguage 448 epSOSMedicalDevices 458 epSOSNullFavor 461 epSOSPackage 462 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 2 of 490 MTC epSOSPersonalRelationship 464 epSOSPregnancyInformation 466 epSOSProcedures 467 epSOSReactionAllergy 470 epSOSResolutionOutcome 472 epSOSRoleClass 473 epSOSRouteofAdministration 474 epSOSSections 477 epSOSSeverity 478 epSOSSocialHistory 479 epSOSStatusCode 480 epSOSSubstitutionCode 481 epSOSTelecomAddress 482 epSOSTimingEvent 483 epSOSUnits 484 epSOSUnknownInformation 487 epSOSVaccine 488 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 3 of 490 MTC epSOSActiveIngredient epSOSActiveIngredient Value Set ID 1.3.6.1.4.1.12559.11.10.1.3.1.42.24 TRANSLATIONS Code System ID Code System Version Concept Code Description (FSN) 2.16.840.1.113883.6.73 2017-01 A ALIMENTARY TRACT AND METABOLISM 2.16.840.1.113883.6.73 2017-01
    [Show full text]